Balfaxar
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- Balfaxar
- Generic name
- PROTHROMBIN COMPLEX CONCENTRATE (HUMAN)
- Manufacturer
- Octapharma USA Inc
- Product type
- PLASMA DERIVATIVE
- SPL set ID
- 68fa4f90-8b01-6498-4140-e0be5247c3fe
- SPL ID
- 5be10bd2-a785-7f3b-0d28-d066cd5f7d24
- Version
- 4
- Effective date
- 2023-07-21
- Source export date
- 2026-11-13
- Source partition
- 11
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0011-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/0ccebc9befe0ec22afe916211b2687f6eef8ed163963720f103786a7f2d2e3ae/drug-label-0011-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 17:32:50
| Harmonized routes |
|---|
| INTRAVENOUS |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | BLA | 125776 | derived:openfda.application_number |
| application number | BLA125776 | openfda.application_number | |
| brand name | Balfaxar | openfda.brand_name | |
| generic name | PROTHROMBIN COMPLEX CONCENTRATE (HUMAN) | openfda.generic_name | |
| manufacturer name | Octapharma USA Inc | openfda.manufacturer_name | |
| ndc | package | 68982-261-02 | openfda.package_ndc |
| ndc | package | 68982-261-81 | openfda.package_ndc |
| ndc | package | 68982-261-01 | openfda.package_ndc |
| ndc | package | 68982-261-82 | openfda.package_ndc |
| ndc | product | 68982-261 | openfda.product_ndc |
| ndc11 | package | 68982026101 | derived:openfda.package_ndc |
| ndc11 | package | 68982026181 | derived:openfda.package_ndc |
| ndc11 | package | 68982026182 | derived:openfda.package_ndc |
| ndc11 | package | 68982026102 | derived:openfda.package_ndc |
| rxcui | 2643209 | openfda.rxcui | |
| rxcui | 2643204 | openfda.rxcui | |
| spl id | 5be10bd2-a785-7f3b-0d28-d066cd5f7d24 | id | |
| spl set id | 68fa4f90-8b01-6498-4140-e0be5247c3fe | set_id | |
| unii | 6U90Y1795T | openfda.unii | |
| unii | 8FB1K07F16 | openfda.unii | |
| unii | 90J3F6N5FN | openfda.unii | |
| unii | 0P94UQE6SY | openfda.unii | |
| unii | 3Z6S89TXPW | openfda.unii | |
| unii | 4156XVB4QD | openfda.unii |
Boxed warning cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
WARNING: ARTERIAL AND VENOUS THROMBOEMBOLIC COMPLICATIONS Patients being treated with Vitamin K antagonist (VKA) therapy have underlying disease states that predispose them to thromboembolic events. Potential benefits of reversing VKA should be weighed against the potential risks of thromboembolic events, especially in patients with the history of a thromboembolic event. Resumption of anticoagulation should be carefully considered as soon as the risk of thromboembolic events outweighs the risk of acute bleeding. Both fatal and non-fatal arterial and venous thromboembolic complications have been reported with BALFAXAR in clinical trials and post marketing surveillance. Monitor patients receiving BALFAXAR for signs and symptoms of thromboembolic events. [see Warnings and Precautions ( 5.2 )]. BALFAXAR may not be suitable in patients with thromboembolic events in the prior 3 months. [see Warnings and Precautions ( 5.2 )]. WARNING: ARTERIAL and VENOUS THROMBOEMBOLIC COMPLICATIONS See full prescribing information for complete boxed warning . Patients being treated with Vitamin K antagonists (VKA) therapy have underlying disease states that predispose them to thromboembolic events. Potential benefits of reversing VKA should be weighed against the potential risks of thromboembolic events, especially in patients with the history of a thromboembolic event. Resumption of anticoagulation should be carefully considered as soon as the risk of thromboembolic events outweighs the risk of acute bleeding. Both fatal and non-fatal arterial and venous thromboembolic complications have been reported with BALFAXAR in clinical trials and post marketing surveillance. Monitor patients receiving BALFAXAR for signs and symptoms of thromboembolic events. ( 5.2 ) BALFAXAR may not be suitable in patients with thromboembolic events in the prior 3 months. ( 5.2 )
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
warnings and cautions
5 WARNINGS AND PRECAUTIONS Discontinue infusion if allergic or anaphylactic-type reactions occur. Initiate appropriate treatment. ( 5.1 ) Arterial and venous thromboembolic complications have been reported in patients receiving BALFAXAR. Monitor patients receiving BALFAXAR for signs and symptoms of thromboembolic events. ( 5.2 ) BALFAXAR is made from human plasma; therefore, may carry the risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent. ( 5.3 ) 5.1 Hypersensitivity Reactions If severe allergic or anaphylactic-type reactions occur, immediately discontinue administration of BALFAXAR and initiate appropriate treatment. Therapeutic measures depend on the type and severity of the undesirable effect. 5.2 Thromboembolic Risk/Complications There is a risk of thrombosis or disseminated intravascular coagulation when patients with acquired deficiency are treated with human prothrombin complex. [ 1 ] Patients given human prothrombin complex should be observed closely for signs or symptoms of disseminated intravascular coagulation or thrombosis. Because of the risk of thromboembolic complications, monitoring of signs and symptoms should be exercised when administering human prothrombin complex to patients with a history of coronary heart disease, patients with liver disease, or to patients at risk of thromboembolic events or disseminated intravascular coagulation. The potential benefit of treatment should be weighed against the risk of complications. BALFAXAR may not be suitable in patients with thrombotic or thromboembolic events in the prior 3 months, as it has not been studied in these patients. Resumption of anticoagulation should be carefully considered following administration of BALFAXAR and vitamin K once the risk of thromboembolic events outweighs the risk of bleeding. 5.3 Transmissible Infectious Agents Standard measures to prevent infections resulting from the use of medicinal products prepared from human blood or plasma include selection of donors, screening of individual donations and plasma pools for specific markers of infection and the inclusion of effective manufacturing steps for the inactivation/removal of viruses. Despite this, when medicinal products prepared from human blood or plasma are administered, the possibility of transmitting infectious agents e.g., viruses, the vCJD agent, and theoretically, CJD agent, cannot be completely eliminated. This also applies to unknown or emerging viruses and other pathogens. The measures taken are considered effective for enveloped viruses such as human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV). The measures taken may be of limited value against non-enveloped viruses such as hepatitis A virus (HAV) and human parvovirus B19 (B19V). B19V infections may be serious for pregnant women (fetal infection) and for individuals with immunodeficiency or increased erythropoiesis, e.g., hemolytic anemia. All suspected infections thought by a physician to have been possibly transmitted by this product should be reported by the physician or other healthcare provider to Octapharma USA Inc. at 1-866-766-4860.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS The most common adverse reactions observed in ≥ 3% of subjects were procedural pain, wound complications, asthenia, anemia, dysuria, procedural vomiting and catheter site related reaction. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Octapharma USA Inc. at 1-866-766-4860 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. _________________________________________________________________________________________________________________________ 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In a prospective, randomized, controlled, double-blind, multicenter non-inferiority trial, 208 subjects who required reversal of vitamin K antagonist induced anticoagulation due to the need for urgent surgery were enrolled; 105 received BALFAXAR and 103 Kcentra. Subjects ranged in age from 31 years to 92 years. Adverse reactions for BALFAXAR and the comparator are described below. Adverse Reactions The most common adverse reactions observed in ≥ 3% subjects receiving BALFAXAR were procedural pain, wound complications, asthenia, anemia, dysuria, procedural vomiting and catheter site related reaction. In the post-surgical setting, serious adverse reactions in BALFAXAR treatment arm included cerebral infarction, and pulmonary embolism as well as hemorrhage, acute respiratory failure, shock, subdural hemorrhage. One subject experienced one serious adverse reaction, unstable angina assessed as related to BALFAXAR. Adverse reactions are summarized for BALFAXAR and Kcentra in the following table: Table 2 Adverse Reactions Reported in More Than 3% Subjects Following BALFAXAR or Kcentra Administration System Organ Class Preferred Term BALFAXAR Subjects (N=105) n (%) Kcentra Subjects (N=103) n (%) Blood and lymphatic system disorders Anemia 6 (5.7%) 6 (5.8%) Gastrointestinal disorders Abdominal pain 3 (2.9%) 5 (4.9%) General disorders and administration site conditions Asthenia 13 (12.4%) 18 (17.5%) Catheter site related reaction 4 (3.8%) 2 (1.9%) Injury, poisoning and procedural complications Postoperative wound complication 15 (14.3%) 15 (14.6%) Procedural pain 50 (47.6%) 50 (48.5%) Procedural vomiting 4 (3.8%) 0 Suture related complication 2 (1.9%) 4 (3.9%) Investigations Blood pressure increased 0 5 (4.9%) Body temperature increased 0 4 (3.9%) Renal and urinary disorders Dysuria 5 (4.8%) 2 (1.9%) Deaths There were a total of four deaths (3.8%) in the BALFAXAR group between 22 and 45 days post surgery, with one (1%) additional death occurring on day 47 just after completion of the study reporting period and one (1%) death in the Kcentra group 10 days after treatment. No deaths were considered to be related to study treatment. Thromboembolic Events There were three subjects (2.9%) with BALFAXAR who experienced four thromboembolic events in the randomized controlled trial in urgent surgery; cerebral infarction, pulmonary embolism, unstable angina and myocardial ischemia. The number of thromboembolic adverse reactions assessed as at least possibly related to study treatment was one (1%) with BALFAXAR (unstable angina). There were no thromboembolic events observed in the Kcentra treatment arm. The following serious adverse reactions are described below and/or elsewhere in the labeling: Hypersensitivity Reactions [ see Warnings and Precautions ( 5.1 ) ] Arterial and venous thromboembolic complications [ see Boxed Warning and Warning s and Precautions ( 5.2 ) ] Possible Transmission of Infectious Agents [ see Warnings and Precautions ( 5.3 ) ] 6.2 Postmarketing Experience Because post-marketing reporting of adverse reactions is voluntary and from a population of uncertain size, it is not always possible to reliably estimate the frequency of these reactions or establish a causal relationship to product exposure. The following adverse reactions have been reported during postmarketing use of BALFAXAR outside the US since 2003: Table 3 Adverse Reactions Reported During Post-Marketing Use of BALFAXAR Immune system disorders Anaphylactic shock, anaphylactic reaction, anaphylactoid reaction, hypersensitivity reaction Nervous system disorders Cerebrovascular accident, headache, paresthesia, tremor Cardiac disorders Bradycardia, tachycardia, cardiac arrest Vascular disorders Thromboembolic events, circulatory collapse, hypotension, hypertension Respiratory, thoracic and mediastinal disorders Dyspnea, respiratory failure Gastrointestinal disorders Nausea Skin and subcutaneous tissue disorders Urticaria, rash, pruritus General disorders and administration site conditions Fever, chills To report SUSPECTED ADVERSE REACTIONS, contact Octapharma USA Inc. at 1-866-766-4860 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
adverse reactions table
<table><thead><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"> System Organ Class </content> <content styleCode="bold"> Preferred Term</content></td><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"> BALFAXAR Subjects (N=105) </content> <content styleCode="bold"> n (%)</content></td><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"> Kcentra Subjects (N=103) </content> <content styleCode="bold"> n (%)</content></td></tr></thead><tbody><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"> Blood and lymphatic system disorders</content></td><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"/><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"/></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> Anemia</td><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 6 (5.7%)</td><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 6 (5.8%)</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"> Gastrointestinal disorders</content></td><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"/><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"/></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> Abdominal pain</td><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 3 (2.9%)</td><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 5 (4.9%)</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"> General disorders and administration site conditions</content></td><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"/><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"/></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> Asthenia</td><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 13 (12.4%)</td><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 18 (17.5%)</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> Catheter site related reaction</td><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 4 (3.8%)</td><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 2 (1.9%)</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"> Injury, poisoning and procedural complications</content></td><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"/><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"/></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> Postoperative wound complication</td><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 15 (14.3%)</td><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 15 (14.6%)</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> Procedural pain</td><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 50 (47.6%)</td><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 50 (48.5%)</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> Procedural vomiting</td><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 4 (3.8%)</td><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 0</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> Suture related complication</td><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 2 (1.9%)</td><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 4 (3.9%)</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"> Investigations</content></td><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"/><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"/></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> Blood pressure increased</td><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 0</td><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 5 (4.9%)</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> Body temperature increased</td><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 0</td><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 4 (3.9%)</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"> Renal and urinary disorders</content></td><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"/><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"/></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> Dysuria</td><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 5 (4.8%)</td><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 2 (1.9%)</td></tr></tbody></table>
adverse reactions table
<table><thead><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"> Immune system disorders</content> Anaphylactic shock, anaphylactic reaction, anaphylactoid reaction, hypersensitivity reaction</td></tr></thead><tbody><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"> Nervous system disorders</content> Cerebrovascular accident, headache, paresthesia, tremor</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"> Cardiac disorders</content> Bradycardia, tachycardia, cardiac arrest</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"> Vascular disorders</content> Thromboembolic events, circulatory collapse, hypotension, hypertension</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"> Respiratory, thoracic and mediastinal disorders</content> Dyspnea, respiratory failure</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"> Gastrointestinal disorders</content> Nausea</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"> Skin and subcutaneous tissue disorders</content> Urticaria, rash, pruritus</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"> General disorders and administration site conditions</content> Fever, chills</td></tr></tbody></table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.